RxDoctor Payments Data

Reylin Segura

Family · San Antonio, TXNPI 1013240852

Payments from drug & device makers

$15,268in general payments, 2019–2025

Across 730 payments — averaging $20.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Johnson & Johnson$1K
  • AstraZeneca$1K
  • Bristol Myers Squibb$776
  • Merck$644
  • Sanofi$619
  • plus $10K from 54 others

What the payments were for

  • Food & beverage$14,68896%
  • Education$5794%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis74$1,386
Johnson & Johnson62$1,261
AstraZeneca(2 entities)52$1,040
Bristol Myers Squibb42$776
Merck26$644
Sanofi29$619
Incyte Corporation29$557
Gilead(2 entities)28$528
Astellas Pharma US Inc19$513
Amgen27$510
E.r. Squibb & Sons, L.L.C.27$502
Takeda Pharmaceuticals U.S.A., Inc.15$417
Bayer14$348
Eisai Inc.20$347
Karyopharm Therapeutics Inc.16$340
Genentech USA, Inc.14$328
GSK16$325
AbbVie13$324
Rigel Pharmaceuticals, Inc.16$319
Daiichi Sankyo Inc.15$312
Pfizer16$298
Sobi, Inc11$276
Pharmaessentia USA Corporation9$260
Ipsen Biopharmaceuticals, Inc13$237
Jazz Pharmaceuticals Inc.9$213
Regeneron Healthcare Solutions, Inc.9$205
Array Biopharma Inc8$183
Sanofi-aventis U.S. LLC2$142
Genmab U.S., Inc.5$140
ADC Therapeutics America, Inc.7$135
AVEO Pharmaceuticals, Inc.6$135
Exelixis Inc.3$130
Organon9$129
Tersera Therapeutics LLC5$108
Kyowa Kirin, Inc.5$107
Seagen Inc.6$99
Deciphera Pharmaceuticals Inc.4$96
Lilly USA, LLC4$94
EMD Serono, Inc.5$87
Morphosys, US Inc.4$85
Dova Pharmaceuticals4$74
Pharmacosmos Therapeutics Inc.3$72
Agios Pharmaceuticals, Inc.3$68
Blueprint Medicines Corporation3$62
Taiho Oncology, Inc.3$50
Boehringer Ingelheim2$44
Adaptive Biotechnologies Corporation2$41
Mirati Therapeutics, Inc.2$34
Octapharma USA, Inc.2$33
Pharmacyclics LLC, An Abbvie Company2$30
Legend Biotech USA Inc.1$26
Sumitomo Pharma America, Inc.1$26
Servier Pharmaceuticals LLC1$26
CTI Biopharma Corp.1$24
Tempus AI, Inc1$22
Amneal Pharmaceuticals LLC1$21
Tolmar, Inc.1$19
Alnylam Pharmaceuticals Inc.1$15
Coherus Oncology, Inc.1$14
AMAG Pharmaceuticals, Inc.1$13

How this compares

$15,268 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$8,528
Medicare patients
22
Services billed
82

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban14$17,826
Anastrozole35$1,103
Exemestane11$925
Ondansetron OdtOndansetron12$282
Alendronate Sodium34$172
Gabapentin18$137
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav11$123
Warfarin Sodium16$79
Prednisone20$66

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$1,261$17,82614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →